Clinical Trials Arena on MSN
ImmunityBio’s glioblastoma regimen boosts survival in mid-stage study
As of 22 January, 19 of the 23 patients who have received treatment are still alive, with the longest evaluable survival ...
US pharma major AbbVie and China’s RemeGen today announced an exclusive licensing agreement for the development, ...
AbbVie and RemeGen are collaborating on RC148, a novel PD-1/VEGF-targeted bispecific antibody already being developed as a ...
In the fight against disease, programmed cell death – also known as apoptosis – is a key protective function of the body. It breaks down cells that are damaged or have undergone dangerous changes.
AbbVie & RemeGen enter exclusive licensing agreement to develop novel bispecific antibody for advanced solid tumours: North Chicago, Illinois Tuesday, January 13, 2026, 14:00 Hrs ...
Aligos Therapeutics Inc. has identified programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of liver cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback